Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:35:55 2024-05-10 EDT After market 15:59:55
94.33 EUR +1.23% Intraday chart for Sanofi 94.47 +0.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Higher Late Afternoon MT
News Highlights : Top Company News of the Day - Friday at 3 PM ET DJ
Sector Update: Health Care Stocks Advance Friday Afternoon MT
Wall St mixed but headed for weekly gains ahead of inflation data RE
Top MIdday Gainers MT
Sector Update: Health Care MT
News Highlights : Top Company News of the Day - Friday at 1 PM ET DJ
Top Midday Stories: Biden to Reportedly Quadruple Chinese EV Tariffs; Novavax Shares Soar on Sanofi Deal News; Protesters Try to Break Into Tesla's Plant in Germany; FDA Pushes Back Approval of Moderna Vaccine MT
CAC40: Signs new records, weekly gain of +3 CF
CAC40: beats record despite rising rates and indecisive W-Street CF
Novavax Stock Price More Than Doubles After COVID-19 Vaccine Licensing Deal With Sanofi MT
News Highlights : Top Company News of the Day - Friday at 11 AM ET DJ
CAC40: new all-time high (8,257), after DAX, AEX, FT-100 CF
Novavax Unveils COVID-19 Vaccine Licensing Deal With Sanofi; Shares Soar MT
Wall St gains ahead of Fed officials' remarks; Dow nears 40,000 mark RE
Trending : Sanofi, Novavax to Develop New Covid-19 Vaccines DJ
Sector Update: Health Care Stocks Edge Higher Premarket Friday MT
Sector Update: Health Care MT
Wall Street Set to Extend Gains on Thursday's Higher-Than-Expect Jobless Claims Report, Lifting US Equity Futures Pre-Bell MT
SANOFI : UBS gives a Buy rating ZD
HEDGE FUND SHAH CAPITAL SAYS NOVAVAX-SANOFI DEAL IS "A STEP IN T… RE
Top Premarket Gainers MT
HEDGE FUND SHAH CAPITAL - NOVAVAX-SANOFI DEAL CONCURS WITH SHAH… RE
Novavax: co-exclusive licensing agreement with Sanofi CF
Indexes already back on top Our Logo
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
93.18 EUR
Average target price
108.1 EUR
Spread / Average Target
+15.97%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi Ventures Into AI-Driven Drug Development In Collaboration With Frontier IP's Exscientia Unit
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW